ArticleAnnals of biomedical engineering2026
Predicted Effects of Patient Variability and Notch Signaling on In Situ Vascular Tissue Engineering.
Article in Annals of biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
In situ vascular tissue engineering aims to create living blood vessel replacements from biodegradable scaffolds. The functionality of these tissue-engineered vascular grafts (TEVGs) has often been limited, with substantial failure rate and outcome variability. Current optimization strategies seem unable to satisfy all requirements for functional TEVGs and the key sources of outcome variability remain unclear. Here, we computationally explored potential sources of TEVG variability and effects of manipulating Notch, a key vascular signaling pathway. We simulated the evolution of a TEVG from a degradable scaffold under varying patient-specific conditions, driven by immuno-mechano-mediated growth and remodeling mechanisms including Notch. Our simulations suggest that differential inflammatory production, scaffold degradation, and scaffold axial pre-stretch are major sources of variability in TEVG outcome. Immobilizing Jagged ligands to the scaffold did not substantially reduce outcome variability in our simulations, but did improve some aspects of TEVG functionality. This intervention may therefore be beneficial in combination with other treatments that compensate for predicted negative effects. Overall, our model may advance future TEVG optimization by incorporating Notch manipulations under various patient-specific conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.